Загрузка...
Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma
Background: Precision therapy for lung cancer will require comprehensive genomic testing to identify actionable targets as well as ascertain disease prognosis. RNA-seq is a robust platform that meets these requirements, but microarray-derived prognostic signatures are not optimal for RNA-seq data. T...
Сохранить в:
| Опубликовано в: : | J Natl Cancer Inst |
|---|---|
| Главные авторы: | , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Oxford University Press
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5051943/ https://ncbi.nlm.nih.gov/pubmed/27707839 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djw200 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|